Home >> People >> Faculty
LANG Jingyu


Professor, Principal Investigator

Laboratory ofCancer Stem Cells and Targeted Therapy

Email: jylang@sibs.ac.cn

Tel: 86-21-54923285

Research Areas: 

We are interesting in the following research area:   

  1. To identify appropriate therapeutic targets for treating breast and gastric cancers based on currently available cancer genomics data.  

  1. To figure out the genetic alternations that causes the resistance to targeted therapeutic agents.   

  1. To elucidate the molecular mechanisms that are responsible for the self-renewal ability and chemo/radio-resistance of cancer stem cells, identify potential therapeutic targets perturbing these processes, and eventually develop appropriate therapeutic agents for treating cancer stem cells, especially in breast and gastric cancer. 


Brief Biography: 


09/1999-07/2005 Ph.D. in Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China 

09/1995-06/1999 B.S. in Biology, Nanjing University, Nanjing, China   

Research Experience

2017-present: Principal Investigator & Professor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences  

01/2017-12/2017: Deputy Chief of CAS Key Laboratory of Stem Cell Biology, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China 

09/2012-12/2016: Professor,Principal Investigator, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine, 

08/2014-12/2016: Director of Assistant, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicin 

04/2012-08/2012: Research Scientist II, Department of Medical Oncology and Ludwig Center for Cancer Research, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA 

12/2005-12/2011: Postdoctoral Fellow, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 


Selected Publications:*Corresponding Author 

  1. Lang JY, Shi Y, Chin YE. Reprogramming Cancer Cells: back to the future. Oncogene, 2013, 32(18):2247-8. 

  2. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, Chang WC, Fang YF, Chen CT, Lang JY, Tu C, Wang Y, Hsu MC, Kuo HP, Ko HW, Shen J, Lee HH, Lee PC, Wu Y, Chen CH, Hung MC. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell, 2013, 23(6): 796-810.  

  3. Wang Y, Ding Q, Yen CJ, Xia WY, Izzo J, Lang JY, Li CW, Miller S, Wang X, Lee DF, Hsu JL, Hsu JM, Huo L, LaBaff A, Liu DP, Huang TH, Lai CC, Tsai FJ, Chang WC, Chen CH, Wu TT, Buttar N, Wang K, Wu Y, Wang H, Ajani, J, Hung MC. The Crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell, 2012, 21(3): 374-87.  

  4. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang QF, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell, 2011, 20(3): 341-356.  

  5. Wei Y, Chen YH, Li LY, Lang J, Yeh SP, Shi B, Yang CC, Yang JY, Lin CY, Lai CC, Hung MC. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol, 2011, 13(1): 87-94. 

  6. Banerjee A, Lang JY, Hung MC, Sengupta K, Banerjee SK, Baksi K, Banerjee DK. Unfolded protein response is required in nu/nu mice microvasculature for treating breast tumor with tunicamycin. J Biol Chem, 2011, 286(33): 29127-29138. 

  7. Zhou J, Chen Y, Lang JY, Lu JJ, Ding J. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol Cancer Res, 2008, 6(2): 194-204.  

  8. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol, 2008, 10(2): 138-48.  

  9. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, Ding Q, Zhang S, Spohn B, Yang Y, Wei Y, Lang JY, Evans DB, Chiao PJ, Abbruzzese JL, Hung MC. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell, 2007, 12(1): 52-65. 

  10. Lang JY, Chen H, Zhou J, Zhang YX, Zhang XW, Li MH, Lin LP, Zhang JS, Waalkes MP, Ding J. Anti-metastasis effect of salvicine on human breast cancer MDA-MB-435 orthotopic xenograft is closely related to Rho-dependent pathway. Clin Cancer Res, 2005, 11(9): 3455-64.